NRSN

NeuroSense Therapeutics Ltd. Ordinary Shares

0.77

USD

NRSN Earnings Reports

Positive Surprise Ratio

NRSN beat 5 of 8 last estimates.

63%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

NeuroSense Therapeutics Ltd. Ordinary Shares earnings per share and revenue

On Mar 25, 2026, NRSN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.10 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.48% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

BioCardia, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.17

Actual

-$0.06

Surprise

+65.40%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

FAQ

What were NeuroSense Therapeutics Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, NeuroSense Therapeutics Ltd. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to NeuroSense Therapeutics Ltd. Ordinary Shares's Q4 2025 earnings?

The stock price moved up 5.48%, changed from $0.73 before the earnings release to $0.77 the day after.

When is NeuroSense Therapeutics Ltd. Ordinary Shares expected to report next?

The next earning report is scheduled for --.

What are the forecasts for NeuroSense Therapeutics Ltd. Ordinary Shares's next earnings report?

Based on -- analysts, NeuroSense Therapeutics Ltd. Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.